Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients

Immunogenicity of recombinant human acid-alpha glucosidase (rhGAA) in enzyme replacement therapy (ERT) is a safety and efficacy concern in the management of late-onset Pompe disease (LOPD). However, long-term effects of ERT on humoral and cellular responses to rhGAA are still poorly understood. To b...

Descripción completa

Detalles Bibliográficos
Autores principales: Masat, Elisa, Laforêt, Pascal, De Antonio, Marie, Corre, Guillaume, Perniconi, Barbara, Taouagh, Nadjib, Mariampillai, Kuberaka, Amelin, Damien, Mauhin, Wladimir, Hogrel, Jean-Yves, Caillaud, Catherine, Ronzitti, Giuseppe, Puzzo, Francesco, Kuranda, Klaudia, Colella, Pasqualina, Mallone, Roberto, Benveniste, Olivier, Mingozzi, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096052/
https://www.ncbi.nlm.nih.gov/pubmed/27812025
http://dx.doi.org/10.1038/srep36182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096052/
https://www.ncbi.nlm.nih.gov/pubmed/27812025
http://dx.doi.org/10.1038/srep36182

Ejemplares similares